0000 000078 16 Jul 2019 | Other | ¥0.02 Per Share |
0000 000078 28 Feb 2018 | Other | ¥0.07 Per Share |
0000 000078 18 Jun 2001 | Other | ¥0.01 Per Share |
0000 000078 27 Apr 1999 | Other | ¥0 Per Share |
13 Jun 2025 (5 Days) Date | | - Cons. EPS | 0.01 EPS |
31 Oct 2024 Date | | - Cons. EPS | 0 EPS |
31 Aug 2024 Date | | - Cons. EPS | 0 EPS |
13 Jun 2024 Date | | - Cons. EPS | - EPS |
23 Apr 2024 Date | | - Cons. EPS | - EPS |
0000 000078 16 Jul 2019 | Other | ¥0.02 Per Share |
0000 000078 28 Feb 2018 | Other | ¥0.07 Per Share |
0000 000078 18 Jun 2001 | Other | ¥0.01 Per Share |
0000 000078 27 Apr 1999 | Other | ¥0 Per Share |
13 Jun 2025 (5 Days) Date | | - Cons. EPS | 0.01 EPS |
31 Oct 2024 Date | | - Cons. EPS | 0 EPS |
31 Aug 2024 Date | | - Cons. EPS | 0 EPS |
13 Jun 2024 Date | | - Cons. EPS | - EPS |
23 Apr 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Feng Zhang CEO | XSHE Exchange | CNE000000X95 ISIN |
CN Country | 8,264 Employees | - Last Dividend | 27 May 2016 Last Split | 7 Aug 1998 IPO Date |
Shenzhen Neptunus Bioengineering Co., Ltd., founded in 1989 and headquartered in Shenzhen, China, is a prominent company specializing in the research and development, production, and sales of a diverse range of medical products. These include Chinese patent medicines, infusion products, and western medicine preparations. The company has carved a niche for itself in the healthcare industry by providing high-quality medications and medical supplies across various therapeutic areas. It is deeply involved in generic drug quality consistency evaluation and offers valuable technical support alongside its comprehensive R&D activities. Additionally, Shenzhen Neptunus extends its services to the distribution of drugs and medical devices, catering to hospitals, medical institutions, and a network of drug retail institutions and distributors, enhancing its role in the medical supply chain by providing essential value-added services.
These tablets are commonly used for managing elevated cholesterol levels and symptoms of menopause, showcasing Neptunus Bioengineering's dedication to cardiovascular health and wellbeing.
A medication designed for the relief of allergic symptoms, such as runny nose, itching of the skin, and watery eyes, illustrating the company’s focus on providing solutions for allergic reactions and related conditions.
Targeted toward combating infectious diseases, these capsules are important for treating tuberculosis, leveraging Neptunus Bioengineering's strength in addressing infectious and serious health conditions.
The company provides significant technical support services aimed at enhancing the quality and efficacy of generic medications, ensuring they meet the rigorous standards for therapeutic equivalence to their branded counterparts.
Shenzhen Neptunus not only manufactures but also distributes a wide range of drugs, medical devices, and supplies, facilitating the comprehensive availability of essential health products to hospitals, institutions, and retailers.
Through its distribution network, the company offers various value-added services designed to enhance the operational efficiency of healthcare providers and drug retailers, showcasing its commitment to supporting the broader healthcare ecosystem.
In addition to the above products and services, Shenzhen Neptunus Bioengineering Co., Ltd. has a diversified portfolio that addresses multiple disease areas, including malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, and respiratory and digestive system diseases. This extensive range underscores the company's role as a key player in the pharmaceutical and bioengineering sector, with a broad impact on public health and medical research.